

Expanded View Figures




Figure EV1. Ceramide and glucosylceramide levels are increased in *S1pr1^{ECKO}* mEC compared to *S1pr1^{fl/fl}*.

A–G LC–MS/MS quantification of total and specific (A–D) ceramides and (E–G) glucosylceramides in *S1pr1^{fl/fl}* and *S1pr1^{ECKO}* mEC after 4-OHT (1 μ M, 72 h) treatment ($n = 5$ /group from two independent EC isolations/group; four mice/EC isolation).

Data information: Data are expressed as mean \pm SEM. *** $P \leq 0.001$. Statistical significance was determined by unpaired t -test.

Source data are available online for this figure.




Figure EV2. S1P inhibits SPT activity via ORM DLs stabilization.

- A RT-PCR for *Ormdl1*, *Ormdl2*, and *Ormdl3* in the presence or absence of S1P (300 nM, 30') ($n = 3$ biological replicates).
 B *Ormdl* isoforms mRNA abundance determined subtracting the Ct of housekeeping 18S from the Ct of *Ormdls* ($n = 8$ biological replicates).
 C, D Quantification of © SPTLC1 and (D) SPTLC2 levels from Fig 1C.
 E, F (E) Western blot analysis for ORM DLs in HUVEC lysates treated with CHX (10 μ M) for the indicated period of time, in the presence or absence of MG132 (10 μ M) or EER1 (10 μ M) and (F) relative quantification.
 G RT-PCR for *Ormdl1*, *Ormdl2*, and *Ormdl3* before and after independent silencing with the corresponding siRNA (40 nM, 72 h) ($n = 4$ biological replicates).

Data information: Western blot and RT-PCR are representative of three or more independent biological replicates. β -ACTIN, loading control. Data are expressed as mean \pm SEM. *** $P \leq 0.001$. Statistical significance was determined by two-way ANOVA with Tukey's post-test (C, D, F) and unpaired t-test (A, G). Source data are available online for this figure.




Figure EV3. ORMDL3 is hydroxylated at P137.

- A HA-ORMDL3 sequence. In green HA-tag; in blue the peptides identified by MS; in red the prolines identified by MS.
 B Graphical representation of the peptides identified by MS and prolines localization.
 C Summary for the peptide containing P137.
 D Ion masses for the amino acids in the peptide.
 E Representative mass spectrometry showing the P137 hydroxylated.




Figure EV4. S1pr3 deletion leads to increased SPT activity and SL levels.

A, B (A) RT-PCR for S1pr3 and (B) SPT activity in mEC after siCTRL or siS1PR3 treatment (40 nM, 72 h) ($n = 4$ biological replicates).

C–E LC–MS/MS quantification of total (C) Ceramide, (D) Glucosylceramide, and (E) Sphingomyelin in murine endothelial cell (mEC) after siCTRL or siS1PR3 treatment (40 nM, 72 h) ($n = 5$ /group from two independent EC isolations/group; 4 mice/EC isolation).

Data information: Data are expressed as mean \pm SEM. $^*P \leq 0.05$; $^{***}P \leq 0.001$. Statistical significance was determined by unpaired t -test.

Source data are available online for this figure.




Figure EV5. Endothelial-derived S1P inhibits SL biosynthesis via S1PR1,3.

A–E LC–MS/MS quantification of specific (A and B) ceramides and (C–E) glucosylceramides in $S1pr1,3^{fl/fl}$ and $S1pr1,3^{ECKO}$ murine endothelial cell (mEC) after 4-OHT (1 μM , 72 h) and siS1PR3 (40 nM, 72 h) treatments ($n = 5$ /group from two independent EC isolations/group; four mice/EC isolation).

F–J LC–MS/MS quantification of specific (F and G) ceramides and (H–J) glucosylceramides in $Spns2^{fl/fl}$ and $Spns2^{ECKO}$ mEC after 4-OHT (1 μM , 72 h) treatment ($n = 5$ /group from two independent EC isolations/group; four mice/EC isolation).

Data information: Data are expressed as mean \pm SEM. $^*P \leq 0.05$; $^{**}P \leq 0.01$; $^{***}P \leq 0.001$. Statistical significance was determined by unpaired t -test.

Source data are available online for this figure.